MJ Biz reports
Global pharma company Jazz Pharmaceuticals has ended patent claims related to its cannabinoid-based epilepsy drug, Epidiolex.
The Ireland-based company, according to Green Market Report, filed its 2023 patent-enforcement lawsuit against a dozen alleged infringers, including:
- Alkem Laboratories
- API Pharma Tech
- Apotex
- Ascent Pharmaceuticals
- Biophore Pharma
- InvaGen Pharmaceuticals and its parent, Cipla USA
- Lupin
- MSN Pharmaceuticals
- Padagis US
- Taro Pharmaceutical Industries
- Teva Pharmaceuticals.
- Zanara Pharma Private
One by one, the defendants reached settlements with Jazz, with Apotex being the last to settle, according to Green Market Report.
In 2021, Jazz acquired United Kingdom-based GW Pharmaceuticals – the developer of Epidiolex and one of the world’s largest medical cannabinoid businesses – for $7.2 billion, a record deal in the space.
Epidiolex has been approved in certain countries for the treatment of seizure disorders, including Canada, which approved the clinically tested drug in 2023 as an “adjunctive therapy” for certain rare and severe forms of epilepsy.
Read More
Pharma giant Jazz dismisses final patent claim involving cannabinoid epilepsy drug
